• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cellular Oncology: Analytical Cellular Pathology >Overexpression of Gastrin-Releasing Peptide Receptors in Tumor-Associated Blood Vessels of Human Ovarian Neoplasms
【24h】

Overexpression of Gastrin-Releasing Peptide Receptors in Tumor-Associated Blood Vessels of Human Ovarian Neoplasms

机译：人卵巢肿瘤肿瘤相关血管中胃泌素释放肽受体的过表达

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Peptide receptors, overexpressed in specific cancers, represent new diagnostic and therapeutic targets. In this study, receptors for the gastrin-releasing peptide (GRP), and other members of the bombesin-family of peptides, were evaluated in ovarian neoplasms.Methods: 75 primary, secondary and metastatic ovarian tumors were investigated for their bombesin-receptor subtype expression, incidence, localization and density usingin vitroautoradiography on tissue sections with the universal radioligand125I-[D-Tyr6, ß-Ala11, Phe13, Nle14]-bombesin(6-14) and the GRP-receptor subtype-preferring125I-[Tyr4]-bombesin.Results: GRP-receptors were detected in 42/61 primary ovarian tumors; other bombesin-receptor subtypes (BB1, bb3) were rarely present (3/61). Two different tissue compartments expressed GRP-receptors: the tumoral vasculature was the predominant site of GRP-receptor expression (38/61), whereas neoplastic cells more rarely expressed GRP-receptors (14/61). GRP-receptor positive vessels were present in the various classes of ovarian tumors; generally, malignant tumors had a higher incidence of GRP-receptor positive vessels compared to their benign counterparts. The prevalence of such vessels was particularly high in ovarian carcinomas (16/19) and their metastases (5/5). The GRP-receptors were expressed in high density in the muscular vessel wall. Normal ovary (n=10) lacked GRP-receptors.Conclusions: The large amounts of GRP-receptors in ovarian tumor vessels suggest a role in tumoral vasculature and possibly angiogenesis. Further, these vessels might be targetedin vivowith bombesin analogs for diagnosis or for therapy.
机译：背景：在特定癌症中过表达的肽受体代表了新的诊断和治疗靶标。在这项研究中，评估了卵巢肿瘤中胃泌素释放肽（GRP）的受体以及该肽的蛙皮素家族的其他成员。方法：调查75种原发性，继发性和转移性卵巢肿瘤的蛙皮素受体亚型放射自显影在具有通用放射性配体125I- [D-Tyr6，ß-Ala11，Phe13，Nle14] -bombesin（6-14）和GRP受体亚型偏爱125I- [Tyr4]-的组织切片上的表达，发生率，定位和密度结果：在42/61原发性卵巢肿瘤中检测到GRP受体;很少出现其他蛙型素受体亚型（BB1，bb3）（3/61）。两种不同的组织区室表达GRP受体：肿瘤脉管系统是GRP受体表达的主要部位（38/61），而肿瘤细胞则很少表达GRP受体（14/61）。在各种类型的卵巢肿瘤中均存在GRP受体阳性血管。通常，恶性肿瘤与良性肿瘤相比，其GRP受体阳性血管的发生率更高。在卵巢癌（16/19）及其转移（5/5）中，这类血管的患病率特别高。 GRP受体在肌肉血管壁上高密度表达。正常卵巢（n = 10）缺乏GRP受体。结论：卵巢肿瘤血管中大量GRP受体提示在肿瘤血管系统和可能的血管生成中起作用。进一步地，这些血管可以用蛙心素类似物体内靶向以进行诊断或治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号